John Q. Trojanowski

TL;DR: It is suggested that the paucity of PHFtau-positive neurites in the ALS/PDC plaques suggests that they reflect pathological aging rather than AD.

TL;DR: The efficacy of another small molecule brain-penetrant MT-stabilizing agent, dictyostatin, is demonstrated in the PS19 tau Tg mouse model, demonstrating improved MT density and reduced axonal dystrophy, with a reduction of tau pathology and a trend toward increased hippocampal neuron survival relative to vehicle-treated PS19 mice.

TL;DR: A systematic functional genomic analysis in purified microglia and bulk tissue from mouse and human AD, FTD, and PSP uncovers a complex temporal trajectory of microglial-immune pathways involving the type 1 interferon response associated with tau pathology in the early stages, followed by later signatures of partial immune suppression and, subsequently, the type 2 interferons response.

TL;DR: A novel radioligand, [125I]TZDM is developed, which binds Aβ fibrils with high affinity, crosses the blood-brain barrier (BBB), and labels amyloid plaques in vivo, and shows differential labeling of SPs in AD brain sections under experimental conditions.

TL;DR: It is demonstrated that Camk2a-directed 208 T DP-43 CTF overexpression is sufficient to cause hippocampal pathology and neurodegeneration in vivo, suggesting an active role for TDP- 43 CTFs in the pathogenesis of FTLD-TDP and related TTP-43 proteinopathies.